Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

aTyr Pharma Names Chief Medical Officer

aTyr Pharma, a San Diego-based biotherapeutics company addressing  rare diseases, has appointed Sanjay Shukla as Chief Medical Officer. Shukla will lead aTyr’s clinical efforts to advance its Physiocrine biology therapeutic intervention points and develop medicines that promote tissue homeostasis for … Continue reading

Posted in Executive Appointments | Tagged , , | Leave a comment

M&A Continues to Dominate the Rare Diseases Landscape

Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Sanofi appoint Chief Patient Officer

Authored by James Sheppard The French pharmaceutical giant Sanofi recently announced that it had appointed Dr Anne C. Beal as its new Chief Patient Officer. This is a new role within Sanofi and one that the company hopes will increase … Continue reading

Posted in Executive Appointments, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , | Leave a comment

Novimmune sees immunotherapy and orphan focus attract new capital

Authored by Karl Simpson Geneva’s biotech cluster has been somewhat tumultuous in recent years . Firstly, Merck Serono decided to close its site in Geneva at a cost of many hundreds of jobs. This was Shire’s gain as they decided … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment

New Enterprise Associates backs veteran rare diseases executive team

Authored by Karl Simpson New Enterprise Associates (NEA) has been showing its increasing appetite for rare disease investments as it puts it recent fund to work. With money already invested in companies like Cydan Corporation (led by Cristina Csimma), KLS … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Ultragenyx follows IPO with Board Appointments

Authored by Karl Simpson It has been a big week for Ultragenyx, the ultra-rare diseases company focused on metabolic genetic disorders. Last Friday they listed on Nasdaq under the ticker “RARE” in an initial public offering of 6,624,423 shares of … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Dr Francois Nader – NPS Pharmaceuticals – Executive Leadership Series

Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Francois Nader performed for NPS Pharmaceuticals in 2013. 2013 Liftstream … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , | Leave a comment

Mr David Mott – NEA – Executive Leadership Series

Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Mr David Mott performed for NEA in 2013. 2013 Liftstream Analysis: NEA scored … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , | Leave a comment

Dr Flemming Ornskov – Shire – Executive Leadership Series

Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Flemming Ornskov performed for Shire in … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

Jazz Pharmaceuticals to acquire rare disease company Gentium

Authored by James Sheppard Jazz Pharmaceuticals, based in Dublin, Ireland, recently announced that it had acquired Italian based rare disease drug company Gentium in a $1bn deal. The deal will give Jazz access to Gentium’s 3 marketed products and extensive … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap